Pregled bibliografske jedinice broj: 1254012
Modulation of Notch signalling pathway in activated hepatic stellate cells has no influence on development or resolution of hepatic fibrosis
Modulation of Notch signalling pathway in activated hepatic stellate cells has no influence on development or resolution of hepatic fibrosis // 5th Meeting of Middle Europe Societies of Immunology and Allergology
Prag, Češka Republika, 2022. 18 P, 1 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1254012 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Modulation of Notch signalling pathway in
activated hepatic stellate
cells has no influence on development or
resolution of hepatic
fibrosis
Autori
Šisl, Dino ; Novak, Sanja ; Kalajzić, Ivo ; Filipović, Maša ; Flegar, Darja ; Šućur, Alan ; Kovačić, Nataša ; Grčević, Danka ; Kelava, Tomislav
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
5th Meeting of Middle Europe Societies of Immunology and Allergology
Mjesto i datum
Prag, Češka Republika, 23.11.2022. - 26.11.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
liver fibrosis, Notch signaling pathway, mouse model, gene expression
Sažetak
We used transgenic mice to investigate the effect selective Notch inhibition or forced activation in activated hepatic stellate cells (aHSCs) has on liver fibrosis. We used two models, carbon tetrachloride (CCl4) treatment and DDC- supplemented diet. The effect of Notch inhibition was investigated in SMACreERT2+/-/RBP- Jfl/fl mice, while Notch activation was studied using SMACreERT2+/- /RosaNICD1 mice. Mice were treated with 75μg/g of tamoxifen i.p. twice weekly. Identically treated Cre- littermates served as controls. CCl4 and DDC caused a similar degree of fibrosis (Sirius red stained area, hydroxyproline content, aminotransferase activities, gene expression of Col1a1 and Acta2) in experimental and control groups in Notch-inhibition as well as Notch-activation experiments. We further tested whether forced Notch activation in aHSCs delays resolution of fibrosis. SMACreERT2+/-/RosaNICD1 mice were treated with either CCl4 or DDC, and tamoxifen for 10 days, and then recovered for one month. Recovery was similar in both SMACreERT2+/-/RosaNICD1 and SMACreERT2-/-/RosaNICD1 mice, suggesting that forced Notch activation doesn’t impair recovery. We also found that tamoxifen per se protects against DDC- induced fibrosis. This was evidenced by a lower Sirius red-stained area, lower hydroxyproline content, and further confirmed by qPCR showing a lower expression of genes for Col1a1, Acta2, Sox9, Pdgf, and Krt19, indicating the inhibitory effect on HSCs, collagen production, and biliary duct proliferation. This effect highlights the importance of a proper Cre- littermate control in this investigation. We conclude that modulation of Notch activity in aHSCs neither changes the degree of liver fibrosis nor does it impair recovery once the noxious stimulus is withdrawn.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
UIP-2017-05-1965 - Uloga Notch signalnog puta u patogenezi jetrene fibroze (NOFIBRO) (Kelava, Tomislav, HRZZ - 2017-05) ( CroRIS)
IP-2018-01-2414 - Notch signaling in osteoclast progenitors induced by rheumatoid arthritis (NORA) (Grčević, Danka, HRZZ - 2018-01) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Ivo Kalajzić
(autor)
Sanja Novak
(autor)
Danka Grčević
(autor)
Alan Šućur
(autor)
Maša Filipović
(autor)
Dino Šisl
(autor)
Tomislav Kelava
(autor)
Nataša Kovačić
(autor)
Darja Flegar
(autor)